ONC
BeOne Medicines Ltd. American Depositary Shares
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
BeOne Medicines (ONC) Stock: Buy, Sell, or Hold?
$421.12
+1.14 (+0.27%)
▲
5d:
+8.75%
30d:
+19.81%
90d:
+21.19%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (18%)
Quality Score
30/100
Position
EXTENDED
30-Day Fair Range
$355.36 – $380.82
Position: EXTENDED
Forward P/E & Valuation
38.9x
FAIR
vs 36.8x historical avg
Wall Street Target
$462.19
+10.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$347.61 / $424.73
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR BETTER ENTRY: ONC is 10.6% above its trading range ($380.82). Market expects 1.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$376.31
Based on 6.9% avg growth
INTRINSIC VALUE TODAY
$233.66
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $421.12, which is considered extended relative to its 30-day fair value range of $355.36 to $380.82. The stock's valuation (Forward PE: 38.9) is in line with its historical norms (36.8). At these levels, the market is pricing in 1.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ONC is in a strong uptrend. The price is approaching resistance at $424.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ONC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $462.19 (+10.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ONC is in a strong uptrend. The price is approaching resistance at $424.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ONC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $462.19 (+10.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$355.36 -
$380.82
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
17.6%
Trading Range & Key Levels
30-Day Trading Range
$355.36 -
$380.82
Current vs Trading Range
EXTENDED
Support Level
$347.61
Resistance Level
$424.73
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Price significantly overextended (+10.6% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($462.19)
- NEUTRAL: Market pricing in 1.9% annual earnings growth - fairly valued
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
38.91
Wall Street Target
$462.19
(+10.1%)
Revenue Growth (YoY)
33.8%
Earnings Growth (YoY)
212.5%
Profit Margin
13.9%
Valuation Premium vs History
+1.9% premium
PE vs Historical
38.9 vs 36.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.9%
(market-implied from PE analysis)
1-Year Target
$427.96
(+2%)
2-Year Target
$436.09
(+4%)
3-Year Target
$444.38
(+6%)
3-Yr Target (if PE normalizes)
(PE: 39→37)
PE COMPRESSION
$420.24
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 38.9, Growth: 9.8%)
$555.43
(+32%)
Base:
(SPY PE: 19.9, Growth: 9.8%)
$283.47
(-33%)
Bear:
(PE: 16.9, Growth: 9.8%)
$240.95
(-43%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (40x PE), but valuation improves significantly next year (39x PE) as earnings recover.
Forward PE: 40.32 | Forward EPS (Implied): $10.42
Bull Case
$507.13
(+21%)
Analyst growth 15.0%, PE expands to 42.3
Base Case
$419.98
(0%)
Market implied 0.0%, PE stable at 40.3
Bear Case
$321.28
(-24%)
Severe decline -15.0%, PE contracts to 36.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share ONC Analysis
Share this live ONC analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 12, 2026 1:29 PM ET
Data refreshes hourly during market hours. Next update: 2:29 PM
Data refreshes hourly during market hours. Next update: 2:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 65 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 37 SELL |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$689 | 58 HOLD |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
15 analysts |
$22 | 67 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ONC Research Pages